Form 4 for JANX Janux Therapeutics, Inc.

Accepted 2023-07-21 00:00:00 ET · period of report 2023-07-19 · accession 0001104659-23-083069 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2023-07-21	2023-07-19	JANX	RA Capital Nexus Fund II, L.P.	Dir	P - Purchase	$12.46	+495.0K	8.12M	+6%	+$6.17M
DI	2023-07-21	2023-07-19	JANX	RA Capital Nexus Fund II, L.P.	Dir	P - Purchase	$12.46	+503.2K	503.2K	New	+$6.27M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-07-19	P	A	495,008	$12.46	8,117,246	I See Footnotes	—	—	(F1) Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on July 18, 2023. (F2) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
2	Derivative	Pre-Funded Warrants (Right to Buy)	2023-07-19	P	A	503,226	$12.46	503,226	I See Footnotes	$0.00 · — to —	503,226 Common Stock	(F5) The Pre-Funded Warrants have no expiration date and are exercisable immediately and will be exercisable until exercise. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the issuer's Common Stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.9% of the Issuer's Common Stock outstanding immediately after giving effect to such exercise. (F3) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").